A Phase 1 Study of AJ1-11095 in Adults with Myelofibrosis Failed by a JAK2 Inhibitor
Research type
Research Study
Full title
A Multicenter, Open-Label, Phase 1 Study of AJ1-11095 Administered as Oral Monotherapy in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
IRAS ID
1013463
Contact name
David Steensma
Contact email
Sponsor organisation
Ajax Therapeutics, Inc.
Clinicaltrials.gov Identifier
Research summary
Myelofibrosis is a blood and bone marrow cancer, where an enzyme, JAK2, is overactive, causing symptoms such as weight loss, fever, and excessive fatigue, as well as an enlarged spleen and often low blood counts including anaemia. Current treatments for myelofibrosis are inadequate.
The purpose of this study is to learn about the effects of the study drug, AJ1-11095, a new kind of JAK2 inhibitor, to find the best dose for treating myelofibrosis and to see how safe AJ1-11095 is for patients with myelofibrosis.
Approximately 40 participants will take part in this study. All participants taking part in this study will receive the study drug, which is taken by mouth once daily.
Participants will remain in the study for about 6 months but may continue to receive treatment for longer if shown to be beneficial.
The effects of AJ1-11095 are not yet known, however, participants will be monitored closely during the trial and informed of potential side effects based on similar medicines.
Participants may or may not benefit from their participation in this study. However, results from this study may benefit others in the future. The information collected may help patients with the same disease get better care in the future.
REC name
London - London Bridge Research Ethics Committee
REC reference
26/LO/0202
Date of REC Opinion
25 Mar 2026
REC opinion
Further Information Favourable Opinion